Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 5/20 | 0.40 |
| ▸ | TACR1 | P25103 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848051 | 0.92 | CNR1 (0.45) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL2159761 | 0.92 | CNR1 (0.46) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL2159388 | 0.89 | CNR1 (0.44) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL2158368 | 0.88 | CNR1 (0.43) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL1848918 | 0.88 | CNR1 (0.45) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL2158648 | 0.87 | CNR1 (0.46) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL1852006 | 0.86 | CNR1 (0.44) | CNR1CNR2TACR2TACR1MEN1 | |
| SCHEMBL1846544 | 0.86 | CNR1 (0.44) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL1849351 | 0.86 | CNR1 (0.45) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL2158511 | 0.86 | CNR1 (0.49) | CNR1CNR2TACR2TACR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324015-B1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-8410137-B2 | Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-8410137-B2 | Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-8410137-B2 | Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| WO-2010012964-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183960-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NR3C2, NR1H3, NR1H2 | HRH3 560/4885KCNH2 1724/4885CNR1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.